Australia's BLS Pharmaceutical soars on strong full-year results

BLS Pharmaceuticals

27/07/2026 04:05

** Shares of BLS Pharmaceutical BLS.AX rise as much as 7.1% to A$0.9, set to mark their steepest intraday pct rise since July 13, if trend holds
** Consumer health and pharma co posts quarterly revenue of A$22.5 million ($15.75 million), up 5% on previous quarter
** FY26 revenue of A$74.98 million, up 156% and at the top end of co's guidance range of A$65 million - A$75 million
** Posts FY26 adjusted EBITDA of A$19 million, up 190% and at the top end of guidance range of A$16.5 million - A$19 million
** Shares up about 103% YTD
     
($1 = 1.4288 Australian dollars)

 (Reporting by Anjali Singh in Bengaluru)
 ((anjali.singh2@thomsonreuters.com;))